News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Canterbury Park Ups Paragon Pharma Stake
November 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Canterbury Park Capital has acquired around 58.2 million additional common shares of Paragon Pharmacies Ltd. (TSX: PGN), for around C$23.2 million. It now holds over 68 million shares, or a 69.9% ownership position.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Mergers & acquisitions
SpringWorks Surges on Potential $3.5B Merck KGaA Buyout
April 25, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer
April 24, 2025
·
2 min read
·
Tristan Manalac
IPO
Swiss ADC Biotech Takes SPAC Track to NASDAQ
April 23, 2025
·
1 min read
·
Annalee Armstrong
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
